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Today there exist two medical applications where relatively strong evidence exists to support the broad adoption of
genome-informed precision medicine. These are the differential diagnosis of single gene diseases and genotype-based
selection of patients for targeted cancer therapies. However, despite the availability of the $1000 genome and
$700 exome for research, there is as yet little broad uptake of genomic medicine, even in these applications.
Significant impediments to mainstream adoption exist, including unavailability in many institutions, lack of
scalability in others, a dearth of physician understanding of interpreted genome or exome results or knowledge
of how to translate consequent precision medicine care plans, and a lack of test reimbursement. In short,
genomic medicine lacks a breakthrough application. Rapid genome sequencing of acutely ill infants with
suspected genetic diseases (STATseq) may become that application when scaled to dozens of trios per day
without loss of timeliness or accuracy. Also critical for broad adoption is embedding STATseq in software for
timely patient ascertainment, augmented intelligence for interpretation, explanation of results for generalist
physicians, and dynamic precision medicine decision support.The Merriam-Webster dictionary defines a Killer, or
breakthrough, Application as “a computer application
of such great value or popularity that it assures the suc-
cess of the technology with which it is associated;
broadly: a feature or component that in itself makes
something worth having or using” [1]. Hitherto, gen-
omic or precision medicine has been technology-
driven. In the mature genomic era, lifestyle, occupation,
and healthcare choices will be bettered for the majority
by genomic guidance [2]. However, in the words of
Mark Kaganovich, “To be the next Internet, genomics
needs its “light bulb moment” — the singularity where
the technology reaches the point where applications
can be built and deployed to the mainstream market
leveraging the infrastructure built for and by previous
applications” [3]. In the parlance of Roger’s Innovation
Adoption Curve, we have entered the chasm between
innovators and early adoptors [4].* Correspondence: sfkingsmore@cmh.edu
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creativecommons.org/publicdomain/zero/1.0/For over a decade, the achievement of the $1000
genome has itself been touted as the breakthrough
application — the key that enables entry into the gen-
omic era of human self-realization, when a person’s
identity becomes increasingly defined by their DNA
code. Thanks to strategic investments by the National
Human Genome Research Institute, as of January 2014,
the $1000 genome became reality [5]. Eighteen months
later, however, it is difficult to discern a consequent
change in genomics other than a larger n (the number
of subjects proposed to be studied) in genomic grant
proposals, a re-ranking of the top 100 genome sequence
providers, and the robust sales of HiSeq XTen systems.
This lack of impact is partly the result of limitations in
this version of the $1000 genome, which include scaling
and turnaround times designed for large research stud-
ies (18,000 genomes per year), and the hidden cost and
lack of commensurate scaling of genome analysis, inter-
pretation, confirmatory studies, reporting, understand-
ing and translation into precision care.
Access to a cheaper genome alone does not account for
the latter, fundamental problems with the incorporation of
genomic health information into medical practice. Medical
genomes today are difficult to comprehend (unintelligible
with byzantine resultant language), slow (typically 3–6ss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Box 1. The five components of newborn screening
precision medicine of selected genetic diseases
(from [43])
1. Screening: Heel-prick testing of newborns at about 24 h of
age. Blood spots (Guthrie cards) are sent to a state newborn
screening lab. Results are returned to the newborn’s physician
within 10–14 days.
2. Follow-up: Rapid location, follow-up, and referral of infants
with positive (abnormal) screening test results.
3. Diagnosis: Structured evaluations of infants with a positive
screening test to make a definitive diagnosis or exclude the
disorder.
4. Management: Rapid planning and implementation of long-term
therapy. Specific management guidelines exist for each
specific disease, and include the required expertise of
healthcare providers, parental health education, health
maintenance, management of acute illness, genetic counseling,
and psychosocial support.
5. Evaluation: Validation of testing procedures, assessment of
the efficiency of follow-up and intervention, and assessment
of the benefit to the patient, family, and society.
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their potential, and most of the information comes with
caveats and qualifications that few physicians under-
stand. There is no quick solution to the paucity of de-
terministic or actionable information that a genome
yields today in a healthy individual or in most common
diseases. What will be the first breakthrough applica-
tion for genomic medicine — the driver application that
overcomes these barriers, persuades patients and physi-
cians that genomes have significant health implications,
and changes the genome from esoteric to the breeze
block with which precision medicine is built?
Two medical applications that are ready for
genome-informed precision medicine
While the full realization of a breakthrough application
for genome-guided precision medicine has yet to be
recognized, there are at least two medical applications
today that may serve as models for genome-informed
precision medicine. These applications have a relatively
high likelihood of yielding acutely actionable information.
Study of these applications can inform the business and
design focus to cross the adoption chasm.
The first is the differential diagnosis of single gene
diseases where there has been longstanding evidence that
a molecular diagnosis at or near disease onset can mark-
edly improve outcomes. Clearly, for the approximate 60
genetic diseases tested by newborn screening (NBS) pro-
grams, this was substantiated by the implementation of a
state precision medicine public health service since the
late 1950s [6–8]. The NBS precision medicine program is
a coordinated system of services with five parts (Box 1).
The genetic diseases tested by NBS were chosen specific-
ally based on the availability of medical therapies that
when implemented immediately decreased morbidity and
mortality, and prevented many, and in some disorders all,
of the serious clinical sequelae. The feasibility and benefit
of early diagnosis for the remaining ~4300 genetic diseases
has started to be addressed in six recent retrospective case
series. Totaling 3587 subjects, these studies reported mo-
lecular diagnostic yields of 27–57 % (Table 1) [9–13]. Fur-
thermore, two of these reported that diagnoses changed
acute clinical management in 49–100 % of patients, find-
ings which start to overcome the general misconception
that nothing can be done for most genetic diseases
(Table 1). While no prospective studies of consequent
change in outcomes have yet been published, the retro-
spective evidence is strengthened by an abundance of
case reports of the clinical utility of genome- or exome-
derived diagnoses.
The second medical application where genome se-
quences have a relatively high likelihood of yielding
acutely actionable information today is in oncology. The
landscape of cancer genomics is rapidly being describedthrough efforts of large collaborative groups, including
The Cancer Genome Atlas (TCGA) of the National Can-
cer Institute (NCI), the International Cancer Genome
Consortium (ICGC), and the Pediatric Cancer Genome
Project [14–16]. Genomic biomarkers have the potential
to aid with cancer diagnosis and classification, prognosis
and, most importantly, molecularly guided treatment [17].
While the diagnosis and treatment of cancer has historic-
ally been based upon histologic findings and extent of dis-
ease, cancers are now being reclassified by molecular
subtype, with treatment tailored to the pathways mutated.
For example, recurrent and potentially targetable genetic
alterations that are predictive of poor outcome have been
described in childhood acute lymphoblastic leukemia
(ALL) [18, 19]. Genotype-based selection of patients for
the application of targeted therapies has already had a
substantial impact on the treatment of some cancers, such
as tyrosine kinase inhibitors in patients with nonsmall cell
lung cancers [20–24]. Furthermore, precision oncology
represents a specialized case of pharmacogenomics, where
genome information can guide both the choice of drug
and the drug exposure, based on ADME (absorption, dis-
tribution, metabolism, and excretion) variants.
Prospective trials of the tumor genome, exome, and gene
panel-guided treatments are now in progress. For example,
the Lung Cancer Master Protocol (Lung-MAP) trial is
Table 1 Results of five large, retrospective case studies of the diagnostic rate of genome or exome sequencing in children with
suspected genetic diseases, particularly neurodevelopmental disabilities
Reference Number of subjects Disease Age in years (mean or median) Diagnosis rate De novo mutation Management changed by diagnosis
[9] 100 NDD 7 47 % 51 % 49 %
[10] 78 NDD 9 41 % 56 % 100 %
[11] 1756 Any 6 27 % 49 % Not examined
[12] 520 Any <18 26 % 50 % Not examined
[13] 1133 NDD 6 27 % 62 % Not examined
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are matched to the genomic makeup of the squamous cell
lung cancer tumors of patients are more effective than the
current standard therapy in halting or reversing the pro-
gress of the disease and in extending the life of the patient
[25]. Other such studies in development are the NCI-
Molecular Profiling-Based Assignment of Cancer Therapy
for Patients With Advanced Solid Tumors (NCI-MPACT;
ClinicalTrials.gov Identifier: NCT01827384), NCI-Molecular
Analysis for Therapy Choice (NCI-MATCH), and Pediatric
MATCH [26, 27]. These prospective trials remain limited
to patients who have exhausted standard treatment
options and who have relapsed and/or have refractory
cancer. Despite a greater understanding of signaling path-
ways, tumor heterogeneity, clonal evolution, treatment re-
sistance, and the importance of epigenomic alterations,
precision oncology is in its infancy [27–31]. The results of
clinical trials incorporating comprehensive genomics data
will help describe the role of next-generation sequencing
in cancer diagnostics and therapeutics [32, 33].
However, neither of these clinical applications has yet
risen to the level of the genomic breakthrough applica-
tion. Physicians generally do not yet practice precision
medicine in such clinical situations. Lack of physician
familiarity with the interpretation of genome or exome
tests, or of the guidelines for changes in management
following genomic test results, undoubtedly explains
part of a slow uptake of physician-ordered testing.
Additionally, in the current era of evidence-based, stan-
dardized management protocols, the use of precision
medicine, focused on individualized care plans, is coun-
terintuitive. Refusal of payors to reimburse clinical ge-
nomes and exomes is also a great hindrance to broad
utilization. However, a less frequently considered issue
is the lack of scalable, timely results. The turnaround
time for results from a medical genome or exome is
typically 6 weeks to 6 months, making the medical gen-
ome possibly the most cumbersome diagnostic test in
the world.
Speed heals
A key ingredient for the breakthrough application of gen-
omic medicine is speed at scale. In medical practice, the
value of information is proportionate to its immediacyrelative to the acuity of the clinical situation. Today, med-
ical genomes — even in the two applications for which
there exists clear evidence of utility — rank as 'last resort'
tests in diagnostic workups because results will not be
available at that clinic visit, or during that on-service
period, or during that hospitalization. Genomes will only
become an integral part of inpatient rounds, surgical pre-
ops, admission orders, newborn panels, and many out-
patient clinics in these two application areas when the
time-to-result routinely matches the acuity of the clinical
situation. Consequently, we think that rapid genome se-
quencing — STATseq — embedded within precision
medicine software programs will be the first breakthrough
application of medical genomics. The STAT in STATseq
comes from the Latin word “statim”, which means imme-
diately. In medical parlance, a blood test that is ordered
STAT is one that needs to be performed as an emer-
gency. The seq in STATseq is an abbreviation for next-
generation sequencing, as in “RNAseq” for RNA sequen-
cing. When we were children, Star Trek was a popular
television and film series. The tricorder was a portable
sensing, computing and recording device used by Star
Trek doctors to help diagnose diseases and collect bio-
marker data about patients. While, ultimately, we desire
the genomic equivalent of the Star Trek medical tricorder,
shortening the scalable turnaround of STATseq to 24 h
using software to guide physician understanding and
provision of precision medicine is needed to catapult med-
ical genomes into the consciousness of physicians.
In 2012, we published a proof of concept paper for
STATseq, in which we showed the feasibility of diagnos-
ing genetic diseases in 50 h through whole genome
sequencing [34]. Of two retrospective cases and four
prospective cases, STATseq yielded a molecular diagno-
sis in five. There were two material developments that
contributed to the 50-h medical genome. First was the
availability of a sequencing instrument that could gener-
ate over 120 GB of DNA sequence in 26 h (the HiSeq
2500 in rapid-run mode). Hitherto, the only high output
run modes that were available took 11 days. The second
was the implementation of informatics processes that
largely automated the search for a diagnosis. Specifically,
the clinical features of an individual patient (the phenome)
were entered, automatically mapped to the canonical
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by the goodness of fit. The genes corresponding to the
genetic disease hits were then orthogonally overlaid on
all genomic variants. When performed together with
variant filtering on the basis of rare occurrence in pop-
ulations, inheritance models, and the evidence of being
pathogenic, this approach frequently can yield a singu-
lar diagnosis. In principle, this process could be auto-
mated, with ascertainment of clinical features from the
electronic medical record, derivation of a comprehen-
sive genetic differential diagnosis, and orthogonal ana-
lysis of filtered genomic variants. Akin to an autopilot,
we envisage augmented intelligence systems supervised
by diagnostic laboratory directors and clinicians.
What are the other practical steps that will reduce
STATseq from 50 h to 18 h and scale from one trio per
week to dozens per day (Fig. 1)? There are several options,
and the good news is that 18 h is within reach in the next
2 years without any transformative, unforeseen, novel
technologies. Firstly, faster sequencing library prepar-
ation and an ultra-rapid run mode are feasible for theStep Near-term
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The second ingredient for the genome breakthrough
application is the ability to automate patient ascertain-
ment, diagnosis, medical translation, and precision clinical
management through the use of software and artificial
(augmented) intelligence. The first medical application ex-
amined for the clinical utility STATseq was genetic disease
diagnosis in acutely ill infants [34]. This population was
selected based on the high prevalence of suspected genetic
disease, the anticipated impact on clinical management,
the perceived need for a more rapid molecular testing
mechanism due to patient acuity, and the high healthcare
costs for this population. Clearly, there exists an immense
unmet medical need in these patients; genetic diseases and
congenital anomalies are the leading cause of death in
infants [40]. Such infants typically are cared for in level
III–IV neonatal intensive care units (NICU) or pediatric
intensive care units (PICUs), facilitating automated ascer-
tainment, and underscoring the need for short turnaround
times not provided by current clinical testing. From a cost-
effectiveness standpoint this is also a unique medical appli-
cation given that costs average $73,000 for a level II–IV
NICU stay and there is potential for more than 70 added
quality-adjusted life years (QALYs) by timely identification
of a treatable condition in an individual infant [41].
Our recent report of initial retrospective experience
with STATseq in this application is informative for un-
derstanding the practical bottlenecks in implementation
of genomic medicine in this population [42]. Thirty-five
infants aged <4 months were enrolled from the NICU
and PICU of our children’s hospital who had an acute
illness of suspected genetic etiology. Despite a goal of
recruitment at birth, in practice the average age at
enrollment for STATseq was day of life 26. Despite the
potential for a 50-h time to result, in practice the me-
dian time to genome analysis was 5 days, and 23 days to
Sanger-confirmed STATseq diagnostic report [42]. While
these times were skewed somewhat due to factors such
as lack of familiarity with STATseq, newly discovered
disease genes and ongoing methods improvements, they
illustrate the current lack of scalability of STATseq, and
need for the technical innovations noted above.
STATseq was very effective for diagnosis of genetic
diseases in these infants. The rate of diagnosis of a genetic
disease was 57 % by STATseq and 9 % by conventional
diagnostic testing; 65 % of STATseq diagnoses were asso-
ciated with de novo mutations, underscoring the need for
simultaneous STATseq of trios (parents and their affected
infant) [42]. Mortality at day of life 100 was 57 % among
infants receiving a genetic diagnosis. Thus, the interval be-
tween the return of results and death was extremely brief,
allowing very limited opportunity for consideration of
precision, nonstandard treatments. Nevertheless, geneticdisease diagnoses frequently had an impact on medical
management. In infants receiving a STATseq diagnosis,
acute clinical utility was observed in 65 %. A strongly
favorable impact on management occurred in 20 % of
diagnoses, and palliative care was instituted in 30 %.
This study showed that, while STATseq is effective for
genetic disease diagnosis in acutely ill infants, patient
ascertainment/enrollment could be considerably earlier
(for example, on the first NICU day), STATseq trio time-
to-result must be fast at scale, and return of results
should be in the setting of infrastructure for immediate
consideration and implementation of precision medicine,
in order to maximize the potential for improved out-
comes. A template for the latter exists; for each genetic
disorder tested by newborn screening programs, the
American College of Medical Genetics has developed: 1)
an ACTion (ACT) sheet that describes the short-term
actions a health professional should follow in communi-
cating with the family and determining the appropriate
steps in the follow-up of the infant that has screened
positive; and 2) an algorithm that presents an overview
of the basic steps involved in determining the final diag-
nosis in the infant. This is accompanied by specific man-
agement guidelines for each specific disease that cover
rapid planning and implementation of long-term therapy
(Box 1) [43].
Given the heterogeneity of genetic diseases, a key next
step for precision NICU medicine is to combine neonatal
genetic diseases into groups for which common, struc-
tured sets of precision interventions can be developed and
implemented at scale. Based on preliminary insights from
our retrospective case series and case reports [42, 44, 45],
we would then envisage return of results of STATseq
together with structured, precision medicine treatment
algorithms. These could either be based on common com-
plications of NICU genetic disease, such as seizures,
hypoglycemia, metabolic acidosis, or cardiac dysrhythmias
(akin to clinical trial designs of LungMAP, NCI-MATCH
and NCI-MPACT in precision oncology), or based on
common molecular pathways of disease. These would in-
clude, for example, ACT sheets for available protein thera-
peutics and medical diets. Where the prognosis is
hopeless, a precision palliative care plan could be elabo-
rated that is calibrated on minimization of infant suffering
and best practices for support of grieving parents and
siblings.
Reimbursement
Historically, payors in the United States have resisted
reimbursement of genetic tests. In part this was because
the individual tests for 4500 disease genes were infre-
quent, the CLIA/CAP licensed laboratories where testing
was predominantly undertaken were small and widely
disbursed, and therefore the lobby for reimbursement
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specialty societies. Now that genetic testing is being
consolidated into genomes, exomes and specific panels,
and amongst fewer laboratories, there is the opportunity,
for the first time, for a unified lobby for reimbursement
of diagnostic testing for rare genetic diseases. Ongoing
efforts to reduce the total cost of clinical genome testing
and to improve the range of types of mutations that are
detected will be important in reimbursement. Also critical,
however, will be prospective, randomized clinical studies
that not only address diagnostic yield of genome sequen-
cing, but also the clinical utility and cost effectiveness of
consequent provision of precision medicine.
Conclusions
A comprehensive system for delivery of acute precision
care is anticipated to be the first breakthrough applica-
tion for genomics in areas such as neonatology and
oncology. As has occurred for other technologies, the
breakthrough application will drive the development of
additional genomics infrastructure investments. These will
include genome-capable electronic medical records, re-
gional genome sequencing capability across the US in
hospitals, and reference laboratories. Likewise, the first
breakthrough application will drive physician and patient
familiarity and acceptance, which will facilitate a second
generation of applications in segments such as pediatric
endocrinology, pediatric neurology, general oncology, and
broader applications of pharmacogenomics.
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